UNASSIGNED: BAFF and IL-21 levels were determined in 66 patients with AIH before treatment and 10 healthy controls. Flow cytometry was performed on circulating B cells of 10 patients with AIH and 12 healthy controls.
UNASSIGNED: Based on BAFF and IL-21 levels, untreated patients with AIH were divided into 3 groups: 27 (41%) patients with normal BAFF and IL-21 (normal BAFF), 27 (41%) patients with elevated BAFF but normal IL-21 (high BAFF), and 12 (18%) patients with elevated IL-21 (high IL-21). The high BAFF group presented with higher bilirubin compared with the normal BAFF and high IL-21 groups (159 vs. 26 vs. 89 μmol/L; p = 0.001; Mann-Whitney U test). After 12 months of treatment, 54% of the high BAFF group reached remission compared with 34% of the normal BAFF group and 0% of the high IL-21 group (p = 0.006, Chi-square test). During follow-up, 3 patients (25%) with high IL-21 developed primary sclerosing cholangitis (PSC) variant syndrome. Autoimmune-associated B cells were increased in patients with AIH compared with healthy controls (4.4 vs. 1.4%; p = 0.003, Mann-Whitney U test). BAFF levels were correlated positively with naïve B cells (p = 0.01) and negatively with class-switched B cells (p = 0.003) and nonclass-switched B cells (p = 0.005, Spearman correlation).
UNASSIGNED: Using BAFF and IL-21, we identified different immunological phenotypes of AIH with a different presentation, treatment response, and outcome. Patients with high IL-21 had the poorest treatment response and a risk of developing PSC variant syndrome. BAFF level was related to shifts in circulating B-cell populations.
UNASSIGNED: In patients with untreated autoimmune hepatitis (AIH), circulating B-cell activating factor of the tumour necrosis family (BAFF), IL-21, and B-cell populations were determined. Three subgroups were identified: with (1) normal BAFF and IL-21, (2) elevated BAFF and normal IL-21, and (3) elevated IL-21. Remission after 1-year treatment occurred in 54, 34, and 0% in Groups 1, 2, and 3, respectively. Group 2 had higher bilirubin, indicating more liver dysfunction. In 25% of patients with high IL-21, AIH-PSC variant syndrome developed, but none in the other groups. Autoimmune-associated B cells were elevated and BAFF levels correlated with certain B cells.
UNASSIGNED:在治疗前66例AIH患者和10例健康对照中测定了BAFF和IL-21水平。对10例AIH患者和12例健康对照者的循环B细胞进行流式细胞术。
未经评估:基于BAFF和IL-21水平,将未经治疗的AIH患者分为3组:BAFF正常和IL-21正常的患者27例(41%),27例(41%)BAFF升高但IL-21正常(高BAFF)的患者,和12名(18%)IL-21升高(高IL-21)的患者。与正常BAFF和高IL-21组相比,高BAFF组呈现较高的胆红素(159vs.26vs.89μmol/L;p=0.001;Mann-WhitneyU检验)。经过12个月的治疗,高BAFF组54%达到缓解,而正常BAFF组为34%,高IL-21组为0%(p=0.006,卡方检验)。随访期间,3例(25%)高IL-21患者发生原发性硬化性胆管炎(PSC)变异综合征。与健康对照组相比,AIH患者的自身免疫相关B细胞增加(4.4vs.1.4%;p=0.003,曼-惠特尼U检验)。BAFF水平与初始B细胞呈正相关(p=0.01),与类别转换B细胞(p=0.003)和非类别转换B细胞呈负相关(p=0.005,Spearman相关性)。
UNASSIGNED:使用BAFF和IL-21,我们鉴定了具有不同表现的AIH的不同免疫表型,治疗反应,和结果。高IL-21患者的治疗反应最差,并且有发生PSC变异综合征的风险。BAFF水平与循环B细胞群的变化有关。
未经证实:在未经治疗的自身免疫性肝炎(AIH)患者中,肿瘤坏死家族的循环B细胞活化因子(BAFF),测定IL-21和B细胞群。确定了三个亚组:(1)正常的BAFF和IL-21,(2)升高的BAFF和正常的IL-21,以及(3)升高的IL-21。治疗1年后,第1、2和3组的缓解率分别为54%、34%和0%。第2组胆红素较高,表明更多的肝功能障碍。在25%的高IL-21患者中,AIH-PSC变异综合征发展,但在其他组中没有。自身免疫相关的B细胞升高,BAFF水平与某些B细胞相关。